Indications and uses
♦ Temporarily relieves nasal congestion due to: ♦ Common cold. Hay fever. Sinusitis ♦ Upper respiratory allergies ♦ Shrinks swollen nasal membranes so you can breathe more freely
♦ Temporarily relieves nasal congestion due to: ♦ Common cold. Hay fever. Sinusitis ♦ Upper respiratory allergies ♦ Shrinks swollen nasal membranes so you can breathe more freely
Adult & children 6 to under 12 years of age (with adult supervision): 2 to 3 sprays in age nostril not more often than every 10 to 12 hours. Do not exceed 2 doses in any 24 –hr period. Children under 6 years of age: ask a doctor. To spray, squeeze bottle quickly and firmly. Do not tilt head backward while spraying. Wipe nozzle clean after use.
♦ Store between 20C to 25C (68 to 77F). ♦ Retain carton for future reference on full labeling.
DRUG FACT
Oxymetazoline hydrochloride, 0.05%
Nasal Decongestant
Do not use more than directed
Stop use and ask a doctor if symptoms persist
If pregnant or breast- feeding, ask a health professional before use.
Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.
Adult & children 6 to under 12 years of age (with adult supervision): 2 to 3 sprays in age nostril not more often than every 10 to 12 hours. Do not exceed 2 doses in any 24 –hr period.
Children under 6 years of age: ask a doctor. To spray, squeeze bottle quickly and firmly. Do not tilt head backward while spraying. Wipe nozzle clean after use.
Benzalkonium Chloride, Edetate Disodium, Glycerin, Polyethelene Glycol, Povidone, Propylene Glycol, Sodium Diphospahte Dibasic, Sodium Phosphate Monobasic, Water.
1-888-995-9935
Manufactured by:
Samson Pharmaceutical
Commerce, CA 90040
Made in USA
Visit our website at
www.samson.pharmaceutical.com
Made in USA
| Class | Version | Type | Effective |
|---|---|---|---|
| OXYMETAZOLINE Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| 726062af-1135-4707-a1d7-57256991bbf9 | Product name | 2 | 20250226 |
| e67be450-f8e4-4bc1-88bd-1259d379f55f | Product name | 1 | 20210127 |
| c53f3286-4062-4cf5-8355-399519c639a6 | Product name | 1 | 20170424 |
| a993dfc5-f219-4460-bde6-30dd724d9ef0 | Product name | 1 | 20160818 |
| 19c71a3d-ed9c-166b-a7e5-38c250c35631 | Product name | 1 | 20140508 |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 20146-4000-2 | 2025-01-30 | C162847 | 48780-1 | 9d75b9cf-eea3-f424-e053-dadaa90a57ce | Breaze ® Nasal Spray Moisturizing |
| 20146-4000-2 | 2023-07-17 | C162847 | 48780-1 | 9d75b9cf-eea3-f424-e053-dadaa90a57ce | Breaze ® Nasal Spray Moisturizing |
| 20146-4000-2 | 2020-01-31 | C162847 | 48780-1 | 9d75b9cf-eea3-f424-e053-dadaa90a57ce | Breaze ® Nasal Spray Moisturizing |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 20146-4000-2 | Breaze Nasal Moisturizing | 1 in 1 CARTON | SPRAY | 1 | 2 | |
| 20146-4000-2 | Breaze Nasal Moisturizing | 30 mL in 1 BOTTLE, SPRAY | SPRAY | 30 | 2 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 20146-4000 | BREAZE NASAL MOISTURIZING (OXYMETAZOLINE HYDROCHLORIDE) SPRAY [SAMSON PHARMACEUTICALS, INC.] | 2 | Legacy NDC, 2 package rows | 20230718_9a165a12-43d3-4e14-a7ba-bfce579430d6.zip |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| Oxymetazoline hydrochloride | ACTIVE INGREDIENT | K89MJ0S5VY | 1 | |
| Oxymetazoline | ACTIVE MOIETY | 8VLN5B44ZY | 1 | |
| Benzalkonium Chloride | INACTIVE INGREDIENT | F5UM2KM3W7 | 1 | |
| Edetate Disodium | INACTIVE INGREDIENT | 7FLD91C86K | 1 | |
| Glycerin | INACTIVE INGREDIENT | PDC6A3C0OX | 1 | |
| Polyethylene Glycols | INACTIVE INGREDIENT | 3WJQ0SDW1A | 1 | |
| Povidones | INACTIVE INGREDIENT | FZ989GH94E | 1 | |
| Propylene Glycol | INACTIVE INGREDIENT | 6DC9Q167V3 | 1 | |
| Sodium Phosphate, Dibasic, Anhydrous | INACTIVE INGREDIENT | 22ADO53M6F | 1 | |
| Sodium Phosphate, Monobasic, Anhydrous | INACTIVE INGREDIENT | KH7I04HPUU | 1 | |
| Water | INACTIVE INGREDIENT | 059QF0KO0R | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 20146-4000 | 20146-4000-2 |
Every source-derived ingredient row is available through these pages.
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| Glycerin | GLYCERIN | PDC6A3C0OX | TABLET, FILM COATED / ORAL | 1.55 mg | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION/ DROPS / OPHTHALMIC | 0.75 %w/v | ||
| Sodium Phosphate, Dibasic, Anhydrous | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | 22ADO53M6F | FILM, SOLUBLE / ORAL | 0.05 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION / RESPIRATORY (INHALATION) | 5 %w/w | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | CAPSULE / ORAL | 5 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | INJECTION / INTRAVENOUS | 33750 mg | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | SHAMPOO / TOPICAL | 1 %w/w | ||
| Sodium Phosphate, Dibasic, Anhydrous | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | 22ADO53M6F | TABLET / ORAL | 96 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION / NASAL | 25 mg/1ml | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | SUSPENSION, EXTENDED RELEASE / ORAL | 1000 mg | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | TAMPON / VAGINAL | 62.1 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | EMULSION / INTRAVENOUS | 2.2 %w/v | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | SPRAY, METERED / NASAL | 240 mg | ||
| Sodium Phosphate, Dibasic, Anhydrous | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | 22ADO53M6F | SOLUTION / OPHTHALMIC | 1.21 %w/v | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | LIQUID / TOPICAL | 2.5 %w/w | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SUSPENSION/ DROPS / OPHTHALMIC | 2.5 %w/v | ||
| Benzalkonium Chloride | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | LIQUID / NASAL | 0.2 mg/1ml | ||
| Povidones | POVIDONE | FZ989GH94E | POWDER, FOR SUSPENSION / ORAL | 35 mg/5ml | ||
| Povidones | POVIDONE | FZ989GH94E | SOLUTION / OPHTHALMIC | 1.8 %w/v | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | CREAM / VAGINAL | 3 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | OINTMENT / TOPICAL | NA | ||
| Sodium Phosphate, Monobasic, Anhydrous | SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS | KH7I04HPUU | SHAMPOO, SUSPENSION / TOPICAL | 1 %w/v | ||
| Sodium Phosphate, Dibasic, Anhydrous | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | 22ADO53M6F | INJECTION, SOLUTION / INTRATHECAL | 1 mg | ||
| Benzalkonium Chloride | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | SUSPENSION/ DROPS / AURICULAR (OTIC) | 0.02 %w/v | ||
| Sodium Phosphate, Dibasic, Anhydrous | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | 22ADO53M6F | TABLET, FILM COATED / ORAL | 0.01 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION / TOPICAL | 1971 mg | ||
| Sodium Phosphate, Monobasic, Anhydrous | SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS | KH7I04HPUU | INJECTION, SOLUTION / INTRAMUSCULAR | 0.62 %w/v | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | JELLY / VAGINAL | NA | ||
| Sodium Phosphate, Dibasic, Anhydrous | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | 22ADO53M6F | CAPSULE, DELAYED RELEASE / ORAL | 43 mg | ||
| Povidones | POVIDONE | FZ989GH94E | SUSPENSION/ DROPS / OPHTHALMIC | 0.6 %w/v | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SOAP / TOPICAL | 0.76 %w/w | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION / DENTAL | 2 %w/w | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION / AURICULAR (OTIC) | 56.55 %w/v | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | TABLET / ORAL | 42 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | INJECTION, SOLUTION / INTRAMUSCULAR | 15 %w/v | ||
| Sodium Phosphate, Monobasic, Anhydrous | SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS | KH7I04HPUU | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 18.81 mg | ||
| Sodium Phosphate, Monobasic, Anhydrous | SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS | KH7I04HPUU | SUSPENSION / ORAL | 65 mg | ||
| Sodium Phosphate, Monobasic, Anhydrous | SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS | KH7I04HPUU | LOTION / TOPICAL | 0.2 %w/w | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | CAPSULE, EXTENDED RELEASE / ORAL | 8 mg | ||
| Sodium Phosphate, Monobasic, Anhydrous | SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS | KH7I04HPUU | SOLUTION / TOPICAL | 0.47 %w/v | ||
| Povidones | POVIDONE | FZ989GH94E | INJECTION / INTRAMUSCULAR | 0.2 %w/v | ||
| Povidones | POVIDONE | FZ989GH94E | IMPLANT / SUBCUTANEOUS | 6 mg | ||
| Benzalkonium Chloride | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | SOLUTION/ DROPS / AURICULAR (OTIC) | 0 %w/v | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | INJECTION / SOFT TISSUE | 0.05 %w/v | ||
| Sodium Phosphate, Dibasic, Anhydrous | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | 22ADO53M6F | INJECTION, SUSPENSION / SOFT TISSUE | 3 mg | ||
| Benzalkonium Chloride | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | SUSPENSION/ DROPS / OPHTHALMIC | 0.02 %w/v | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | LOTION / TOPICAL | 3990 mg | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | INJECTION, SOLUTION / INTRAVENOUS | 4000 mg | ||
| Sodium Phosphate, Monobasic, Anhydrous | SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS | KH7I04HPUU | INJECTION, SUSPENSION / INTRALESIONAL | 10 mg | ||
| Sodium Phosphate, Monobasic, Anhydrous | SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS | KH7I04HPUU | SOLUTION / OPHTHALMIC | 0.78 %w/v | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | AEROSOL / TOPICAL | 3 %w/w | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | LIQUID / NASAL | 2 mg/1ml | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | DROPS / ORAL | 200 mg/1ml | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 6 mg | ||
| Propylene Glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | GEL / VAGINAL | 750 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION/ DROPS / OPHTHALMIC | 12 mg | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | INJECTION, SOLUTION / INTRAVENOUS | 7 mg | ||
| Sodium Phosphate, Dibasic, Anhydrous | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | 22ADO53M6F | TABLET, FOR SUSPENSION / ORAL | 60 mg | ||
| Sodium Phosphate, Monobasic, Anhydrous | SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS | KH7I04HPUU | TABLET, DELAYED RELEASE / ORAL | 23.4 mg | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | TABLET, EFFERVESCENT / ORAL | 32 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 9d8946cd-3361-4f00-b90f-d68e8ca57da1 | 9a165a12-43d3-4e14-a7ba-bfce579430d6 | 2022-11-29 | Warnings | 9d8946cd-3361-4f00-b90f-d68e8ca57da1 9a165a12-43d3-4e14-a7ba-bfce579430d6 |
Adverse event summaries are temporarily unavailable. Other product information remains available.